Steven Lichtman
Stock Analyst at William Blair
(2.64)
# 2,015
Out of 5,241 analysts
74
Total ratings
37.04%
Success rate
7.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENOV Enovis | Assumes: Outperform | n/a | $25.25 | - | 1 | Apr 17, 2026 | |
| MMED MiniMed Group | Initiates: Outperform | n/a | $10.88 | - | 1 | Mar 31, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $13.53 | +62.60% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $152.49 | +139.36% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $55.92 | +123.53% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $65.09 | +56.71% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $85.14 | +58.56% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $2.99 | +301.34% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $65.97 | +66.74% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $77.32 | +21.57% | 10 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $65 | $6.00 | +983.33% | 8 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $5.5 | $14.88 | -63.04% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $11.07 | +8.40% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $63.71 | +36.57% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 | $3.36 | +3,025.00% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $313.22 | -8.05% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $142.18 | -26.15% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $32.31 | +364.25% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $60.94 | +39.48% | 3 | Sep 4, 2020 |
Enovis
Apr 17, 2026
Assumes: Outperform
Price Target: n/a
Current: $25.25
Upside: -
MiniMed Group
Mar 31, 2026
Initiates: Outperform
Price Target: n/a
Current: $10.88
Upside: -
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $13.53
Upside: +62.60%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $152.49
Upside: +139.36%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $55.92
Upside: +123.53%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $65.09
Upside: +56.71%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $85.14
Upside: +58.56%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $2.99
Upside: +301.34%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $65.97
Upside: +66.74%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $77.32
Upside: +21.57%
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $6.00
Upside: +983.33%
May 9, 2024
Maintains: Outperform
Price Target: $5 → $5.5
Current: $14.88
Upside: -63.04%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $11.07
Upside: +8.40%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $63.71
Upside: +36.57%
Sep 19, 2023
Reiterates: Outperform
Price Target: $105
Current: $3.36
Upside: +3,025.00%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $313.22
Upside: -8.05%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $142.18
Upside: -26.15%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $32.31
Upside: +364.25%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $60.94
Upside: +39.48%